Noevir Holdings Co., Ltd. (4928) AI Stock Analysis

• Market Cap: ¥158.14B
• Dividend Yield: 4.88%
• Average Volume (3M): 77.69K
• Price to Earnings (P/E): 20.8
• Beta (1Y): 0.41
• Revenue Growth: -1.63%
• EPS Growth: 1.81%
• Country: JP
• Employees: 1,369
• Sector: Consumer Defensive
• Sector Strength: 44
• Industry: Household & Personal Products
• EPS (TTM): 43.39
• Shares Outstanding: 34,156,624
• 10 Day Avg. Volume: 102,920
• 30 Day Avg. Volume: 77,690
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,082.00
• Price Target Upside: 10.24% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Outperform
• Price Target: ¥5,082.00 ▲(10.24% Upside)

Noevir Holdings scores well due to its strong financial performance and attractive valuation, with a high dividend yield. The technical analysis suggests some short-term weakness, but the long-term trend remains positive. The absence of recent earnings call data and corporate events means these factors do not influence the score.

Noevir Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

Noevir Holdings Co., Ltd. is a Japanese company that operates primarily in the beauty and health sectors. The company is known for developing, manufacturing, and selling a wide range of cosmetics, skincare products, and health-related goods. Noevir's offerings cater to both individual consumers and professional markets, with a focus on high-quality, innovative personal care solutions. Additionally, the company is involved in the pharmaceuticals and nutritional supplements sectors, providing a diversified portfolio of products that promote overall well-being.

How the Company Makes Money

Noevir Holdings Co., Ltd. generates revenue primarily through the sale of its cosmetics and skincare products, which are distributed via direct sales channels, retail stores, and online platforms. The company's revenue model is supported by a strong network of sales representatives and partnerships with retail chains. Additionally, Noevir benefits from its presence in the health care and nutritional supplements markets, where it sells various products aimed at enhancing health and wellness. The company also engages in research and development to continually innovate its product offerings, thereby maintaining a competitive edge in the beauty and health industries.

Noevir Holdings Co., Ltd. Financial Statement Overview

Summary

Noevir Holdings demonstrates strong financial health with consistent profitability and a solid balance sheet. While revenue has recently declined, the company maintains efficient operations and low leverage. Cash flow metrics are stable, though there is potential for enhanced cash flow management.

Income Statement

Noevir Holdings shows strong profitability with a consistent gross profit margin around 67% and a stable net profit margin of approximately 12.5%. However, the recent TTM data indicates a slight revenue decline of 2.1%, contrasting with previous growth trends. EBIT and EBITDA margins remain healthy, reflecting efficient operations.

Balance Sheet

The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.016, indicating minimal leverage. Return on equity is strong at 16.1%, showcasing effective use of equity. The equity ratio is solid, reflecting a stable financial position.

Cash Flow

Operating cash flow to net income ratio is moderate at 0.62, and free cash flow to net income ratio is healthy at 0.74. Free cash flow growth is positive at 8.5% in the TTM period, although it has fluctuated in prior years. Cash flow management appears stable but with room for improvement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	62.87B	63.82B	62.55B	61.14B	51.27B	51.84B
Gross Profit	42.40B	43.16B	42.56B	42.09B	33.03B	33.08B
EBITDA	11.77B	12.44B	12.24B	11.57B	10.05B	9.76B
Net Income	7.60B	7.97B	7.67B	7.59B	6.38B	5.62B
Balance Sheet
Total Assets	73.36B	76.47B	77.25B	76.78B	80.45B	80.05B
Cash, Cash Equivalents and Short-Term Investments	25.47B	29.22B	28.88B	29.75B	31.10B	29.46B
Total Debt	764.00M	828.00M	914.00M	1.00B	1.11B	1.22B
Total Liabilities	22.97B	22.57B	24.04B	24.40B	28.22B	27.81B
Stockholders Equity	49.82B	53.48B	52.79B	52.05B	51.93B	51.98B
Cash Flow
Free Cash Flow	5.51B	8.11B	6.57B	5.23B	8.63B	5.67B
Operating Cash Flow	7.40B	9.12B	7.62B	5.84B	9.06B	7.31B
Investing Cash Flow	-12.13B	1.52B	-3.54B	-255.00M	-416.00M	-1.61B
Financing Cash Flow	-7.87B	-7.71B	-7.49B	-7.38B	-7.18B	-6.96B

Noevir Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4610.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4928, the sentiment is Neutral. The current price of 4610 is below the 20-day moving average (MA) of 4654.75, above the 50-day MA of 4559.40, and above the 200-day MA of 4469.07, indicating a neutral trend. The MACD of 14.76 indicates Positive momentum. The RSI at 51.26 is Neutral, neither overbought nor oversold. The STOCH value of 58.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4928.

Noevir Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4928	70 Outperform	¥158.14B	20.80		4.88%	-1.63%	1.81%
Sector *	62 Neutral	$20.49B	14.73	-2.69%	3.15%	1.98%	-5.13%
KBYPF	―	$2.74B	35.14	5.72%	1.84%	―	―
KOSCF	―	$2.23B	111.46	1.11%	2.88%	―	―
LIOPF	―	$2.98B	21.67	7.29%	2.87%	―	―
PORBF	―	$1.96B	45.73	3.99%	5.35%	―	―
4911	49 Neutral	¥959.77B	496.62		2.06%	-3.60%	-112.93%

Noevir Holdings Co., Ltd. Corporate Events

Noevir Holdings Reports Decline in Nine-Month Financial Results

Noevir Holdings Co., Ltd. reported a decline in its financial performance for the first nine months of the fiscal year ending September 30, 2025, with net sales and operating income both experiencing decreases compared to the previous year. Despite the downturn, the company maintains its dividend forecast and anticipates slight growth in net sales and income for the full fiscal year, suggesting a cautious optimism in its future operations.